Literature DB >> 8887746

Necrosis and apoptosis associated with distinct Ca2+ response patterns in target cells attacked by human natural killer cells.

Y Oshimi1, K Oshimi, S Miyazaki.   

Abstract

1. During the process of cell death, rises in cytosolic Ca2+ concentration ([Ca2+]i) together with structural changes were investigated in target cells attacked by purified CD3-,CD16+ human natural killer (NK) cells. 2. In the target cell line K562, a rapid [Ca2+]i rise to 1-2 microM occurred a few minutes after NK cell-target cell contact, immediately followed by leakage of the Ca2+ indicator dye fura-2 from the cell. Cells were permeabilized, but their chromatin was not fragmented. The changes were basically consistent with those seen in necrosis induced by activated complement. 3. In the target cell line MOLT-4, which expressed the apoptosis-inducing surface antigen Fas much more strongly than K562, the majority of attacked cells displayed a [Ca2+]i rise to 0.7-1 microM followed by a slow decline, often associated with diminishing [Ca2+]i oscillations. As a whole, [Ca2+]i remained higher than 150 nM for at least 1.5-3 h (approximately 100 nM in control cells). 4. MOLT-4 cells attacked by NK cells became bubble shaped within 20 min of the main [Ca2+]i rise reaching its peak, and then both the cell and chromatin were fragmented into small pieces. These findings were basically consistent with those in apoptosis induced by a monoclonal antibody against the surface antigen Fas. 5. NK cells induced both necrosis and apoptosis in cell lines insensitive to NK cells in the presence of an antibody against the major histocompatibility complex class I (antibody-dependent cell-mediated cytotoxicity, ADCC). The distinct Ca2+ responses patterns described above corresponded to necrosis or apoptosis in different cells stimulated by the common ADCC pathway. 6. Human NK cells were found to be capable of inducing necrosis (membrane damage) or apoptosis (nuclear damage) depending on the target cell types. The characteristic Ca2+ response profile was a good indicator for distinguishing between the modes of cell death induced by the cytotoxicity of the killer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887746      PMCID: PMC1160794          DOI: 10.1113/jphysiol.1996.sp021596

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  26 in total

Review 1.  Role of perforin in lymphocyte-mediated cytolysis.

Authors:  H Yagita; M Nakata; A Kawasaki; Y Shinkai; K Okumura
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

Review 2.  A central role of perforin in cytolysis?

Authors:  E R Podack; H Hengartner; M G Lichtenheld
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis.

Authors:  B P Morgan; J R Dankert; A F Esser
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

Review 4.  Apoptosis.

Authors:  J J Cohen
Journal:  Immunol Today       Date:  1993-03

5.  Target-cell sensitivity to natural killer-cell lysis is determined by the expression of a novel antigen in conjunction with major histocompatibility complex class-I molecules.

Authors:  D T Harris; L Jaso-Friedmann; D L Evans
Journal:  Scand J Immunol       Date:  1994-01       Impact factor: 3.487

Review 6.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01

7.  Sequential activation and lethal hit measured by [Ca2+]i in individual cytolytic T cells and targets.

Authors:  M Poenie; R Y Tsien; A M Schmitt-Verhulst
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

8.  Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes.

Authors:  K Oshimi; Y Oshimi; M Satake; H Mizoguchi
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

9.  Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death).

Authors:  M C Peitsch; B Polzar; H Stephan; T Crompton; H R MacDonald; H G Mannherz; J Tschopp
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

10.  A natural killer cell granule protein that induces DNA fragmentation and apoptosis.

Authors:  L Shi; R P Kraut; R Aebersold; A H Greenberg
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  6 in total

1.  ATP-induced Ca2+ response mediated by P2U and P2Y purinoceptors in human macrophages: signalling from dying cells to macrophages.

Authors:  Y Oshimi; S Miyazaki; S Oda
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

2.  Optimized nanosecond pulsed electric field therapy can cause murine malignant melanomas to self-destruct with a single treatment.

Authors:  Richard Nuccitelli; Kevin Tran; Saleh Sheikh; Brian Athos; Mark Kreis; Pamela Nuccitelli
Journal:  Int J Cancer       Date:  2010-10-01       Impact factor: 7.396

3.  Mechanisms of villous atrophy in autoimmune enteropathy and coeliac disease.

Authors:  R Ciccocioppo; S D'Alo; A Di Sabatino; R Parroni; M Rossi; C Doglioni; M G Cifone; G R Corazza
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  Real-Time dynamics of Ca2+, caspase-3/7, and morphological changes in retinal ganglion cell apoptosis under elevated pressure.

Authors:  Jae Kyoo Lee; Siyuan Lu; Anupam Madhukar
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

5.  Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death.

Authors:  H-R Kim; K Kim; K-H Lee; S J Kim; J Kim
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 6.  To Kill But Not Be Killed: Controlling the Activity of Mammalian Pore-Forming Proteins.

Authors:  Patrycja A Krawczyk; Marco Laub; Patrycja Kozik
Journal:  Front Immunol       Date:  2020-11-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.